The Latest Breaking News from American Diabetes Association

Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoarthritis pain in adults with obesity. Patients also experienced substantial weight loss. These findings were shared at an American Diabetes Association conference. Retatrutide targets multiple hormones related to obesity and…

Five scientists were removed from a diabetes conference for distributing an editorial criticising the Trump administration's biomedical science policies, leading to a ban from the event.

In addition to changes in standards for weight control, blood pressure and cholesterol management, the revisions are also intended to address racial disparities in care.

Tracey Brown, president of Walgreens' $109 billion retail business, wants the pharmacy chain to be a one-stop shop for health advice and everyday consumer goods.

The recent passage of legislation that would limit the cost of insulin for Medicare patients has renewed hope for those pushing for Congress to do more

Reining in the soaring prices of insulin has thus far been elusive in Congress, although Democrats say they’ll try again — as part of their economic package that focuses on health and climate

Eli Lilly And Co (NYSE:LLY) presented new data from a mechanism of action study and new analyses of the global registration program for Mounjaro (tirzepatide) injection at the American Diabetes Association. At 28 weeks, participants taking Mounjaro (N=45) had significantly greater reductions in weight and fat mass compared to Novo Nordisk A/S's (NYSE:NVO) injectable Ozempic…